Home Newsfeeds Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61.

byBenzinga Newsdesk

October 14, 2022

1 minute read

Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61.

This Analyst Has Raised Expectaions For Sony – Sees PS5 Growth From New Model

By Anusuya Lahiri

November 10, 4:36 PM

Benchmark analyst Mike Hickey reiterated a Buy rating on Sony Group Corp (NYSE: SONY) with a

SONY

Nano Dimension’s Dissident Shareholder Murchison Ltd.’s Owner, Marc Bistricer’s Case Is Scheduled For Continued Hearing Processes During The Rest Of 2023 Before Capital Markets Tribunal In Canada

By Happy Mohamed

August 25, 9:33 AM

Bistricer Accused of Profiting by Violating Public Retail Investors' Interest and Canadian Securities Law Capital Markets Tribunal Hearing is On Illegal Trading Activity Negates Good

NNDM

Analyst Ratings

6 Analysts Have This To Say About Aptiv

By Benzinga Insights

May 3, 3:00 PM

6 analysts have shared their evaluations of Aptiv (NYSE:APTV) during the recent three months, expressing a mix of…

APTV

Seelos Therapeutics Announces Receipt Of Minutes From Its End Of Phase II Meeting With The U.S. FDA Highlighting Modifications To The Primary And Secondary Endpoints Of Its Phase II Study Of SLS-002

By Benzinga Newsdesk

January 22, 9:01 AM

Company plans to continue its previously announced potential partnership discussions and expects to proceed to Phase III with SLS-002 in Adults with Major Depressive Disorder (MDD) at Imminent Risk of SuicideNEW YORK,

SEEL

Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

Related Posts

This Analyst Has Raised Expectaions For Sony – Sees PS5 Growth From New Model

Nano Dimension’s Dissident Shareholder Murchison Ltd.’s Owner, Marc Bistricer’s Case Is Scheduled For Continued Hearing Processes During The Rest Of 2023 Before Capital Markets Tribunal In Canada

6 Analysts Have This To Say About Aptiv

Seelos Therapeutics Announces Receipt Of Minutes From Its End Of Phase II Meeting With The U.S. FDA Highlighting Modifications To The Primary And Secondary Endpoints Of Its Phase II Study Of SLS-002